Results 151 to 160 of about 7,115 (194)
Central-variant posterior reversible encephalopathy syndrome mimicking tumor progression in a glioblastoma patient on bevacizumab: illustrative case. [PDF]
J Neurosurg Case LessonsKobayashi Y +6 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Discovery of olmesartan hexetil: A new potential prodrug of olmesartan
Bioorganic and Medicinal Chemistry Letters, 2013Synthesis of a new ester prodrug of olmesartan, olmesartan hexetil (1), is described. It is in vitro stabilities and in vivo pharmacokinetics (PK) were evaluated. It showed high stability in simulated gastric juice, and was rapidly hydrolyzed to olmesartan in rat liver microsomes and rat plasma in vitro.
Mohammed I El-Gamal +2 more
exaly +3 more sources
2017
Olmesartan is an angiotensin receptor blockers with actions similar to those of losartan; it is used for the treatment of high blood pressure by relaxing blood vessels for this reason blood can flow more easily. It could be used alone or in combination with other antihypertensive drugs.
Abdulrahman A, Al-Majed +3 more
+5 more sources
Olmesartan is an angiotensin receptor blockers with actions similar to those of losartan; it is used for the treatment of high blood pressure by relaxing blood vessels for this reason blood can flow more easily. It could be used alone or in combination with other antihypertensive drugs.
Abdulrahman A, Al-Majed +3 more
+5 more sources
Drugs, 2002
Olmesartan medoxomil is a nonpeptide angiotensin II receptor antagonist which selectively and competitively inhibits the type 1 angiotensin II receptor without affecting other receptors regulating the cardiovascular system. In well designed randomised trials, olmesartan medoxomil was significantly more effective than placebo, and at dosages of 10 to 20
Gregory T, Warner, Blair, Jarvis
openaire +2 more sources
Olmesartan medoxomil is a nonpeptide angiotensin II receptor antagonist which selectively and competitively inhibits the type 1 angiotensin II receptor without affecting other receptors regulating the cardiovascular system. In well designed randomised trials, olmesartan medoxomil was significantly more effective than placebo, and at dosages of 10 to 20
Gregory T, Warner, Blair, Jarvis
openaire +2 more sources
Olmesartan Medoxomil/Amlodipine
Drugs, 2009black triangle Olmesartan medoxomil/amlodipine is a fixed-dose combination of olmesartan medoxomil and amlodipine, both established antihypertensive agents. Dose titration with the individual constituent drugs is recommended before switching to the equivalent fixed-dose combination.
Mark, Sanford, Susan J, Keam
openaire +2 more sources
Case Study: Olmesartan Medoxomil: A Prodrug of Olmesartan
2008Olmesartan is a durable, specific, and competitive nonpeptide angiotensin II receptor antagonist used to treat hypertension. To achieve better oral bioavailability its ester prodrug, olmesartan medoxomil, was developed. Olmesartan medoxomil is suitable for once daily oral administration and is available in tablet form.
openaire +1 more source